Hot Blood
Executive Summary
The prospect of applying DNA testing to blood screening is likely to shake up the {status quo} in the blood banking industry. The blood banking business is currently dominated by Ortho/Chiron and Abbott Laboratories but now companies with DNA proficiency are seeking to get a piece of the action. Roche Diagnostics is already selling DNA screening tests to blood banks in Europe and it is working on a high-volume instrument specifically geared for blood banks.
You may also be interested in...
Blood Brothers: Chiron and Gen-Probe
The FDA's approval of Procleix HIV-1/ HCV combination assays all but cemented Chiron and Gen-Probe's dominance of DNA-based screening of the US blood supply. The approval changes the economics of providing HIV/ HCV screening to blood banks. The blood banks had been using Procleix or two separate tests supplied by Roche under IND status, paying at cost. Now, they have to pay commercial prices for Procleix. The hike is stretching budgets, but, for a variety of reasons, still more than 70% of US blood banks use Procleix, which is a combination of two assays on one sample.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.